Cisen Pharmaceutical Co., Ltd., together with its subsidiaries, research, develops, produces, and sells drug products. The company’s chemical preparations inclu...
National Healthcare Security Administration: Key drug "Deferasirox" for treating "thalassemia" included in medical insurance
CISEN released its performance for the first three quarters, with a net profit attributable to the parent company of 382 million yuan, a year-on-year decrease of 4.05%
The influenza sector has risen again, with CISEN and TY PHAR. both hitting the daily limit
Innovative drug concept stocks continue to be active, HUAPONT LIFE SCIENCES hits the limit up
CISEN: SSY GROUP completed the reduction of 4.52 million shares, with its shareholding decreasing to 5.11%
Institutions sold 18 stocks including SourceCode Technology today, and bought CISEN for 116 million yuan